MABEL (Minimum Anticipated Biological Effect Level) ๊ธฐ๋ฐ˜ ์šฉ๋Ÿ‰ ์„ค์ •
2025. 4. 26. 00:37
๋ฐ˜์‘ํ˜•

๐Ÿงฌ MABEL (Minimum Anticipated Biological Effect Level) ๊ธฐ๋ฐ˜ ์šฉ๋Ÿ‰ ์„ค์ •


๐Ÿ“Œ MABEL์ด๋ž€?

์•ฝ๋ฆฌํ•™์  ๋ฐ˜์‘์ด ์ตœ์ดˆ๋กœ ๊ธฐ๋Œ€๋˜๋Š” ์ตœ์†Œ ์šฉ๋Ÿ‰

= ๋น„๋…์„ฑ ๊ธฐ์ค€์ด ์•„๋‹Œ "ํšจ๊ณผ" ๊ธฐ์ค€์œผ๋กœ ๊ณ„์‚ฐ๋œ ์ดˆ๊ธฐ์šฉ๋Ÿ‰

๋ฉด์—ญ์กฐ์ ˆ์ œ, ๋‹จ์ผํด๋ก ํ•ญ์ฒด, ์„ธํฌ/์œ ์ „์ž ์น˜๋ฃŒ์ œ์ฒ˜๋Ÿผ

๊ณ ์œ„ํ—˜ ์ƒ๋ฌผ์˜์•ฝํ’ˆ์˜ ์ž„์ƒ 1์ƒ ์ดˆ๊ธฐ ์šฉ๋Ÿ‰ ์„ค๊ณ„์— ํ•„์ˆ˜.


โš™๏ธ MABEL ๊ณ„์‚ฐ ํ๋ฆ„

  1. in vitro ์•ฝ๋ฆฌ ํ™œ์„ฑ ๋ฐ์ดํ„ฐ
    • ์ˆ˜์šฉ์ฒด ๊ฒฐํ•ฉ์นœํ™”๋„ (KD)
    • ECโ‚…โ‚€, ICโ‚…โ‚€ (์„ธํฌ ๊ธฐ์ค€)
    • target cell์˜ ์ˆ˜์šฉ์ฒด ๋ฐœํ˜„ ์ˆ˜์ค€
  2. in vivo ์ตœ์†Œ ์œ ํšจ ์šฉ๋Ÿ‰
    • ๋™๋ฌผ๋ชจ๋ธ PK/PD (์˜ˆ: ์ƒ์ฒด์ง€ํ‘œ, ์ข…์–‘ ํฌ๊ธฐ ๊ฐ์†Œ)
  3. PD Marker ๊ธฐ๋ฐ˜ Human Effect ์ถ”์ •
    • ํ˜ˆ์ค‘ ๋†๋„ vs ํšจ๊ณผ ๊ณก์„ 
  4. PBPK/PK ๋ชจ๋ธ ์‹œ๋ฎฌ๋ ˆ์ด์…˜
    • ์‚ฌ๋žŒ์—์„œ ์˜ˆ์ธก ๋†๋„ ์ถ”์ •
    • ์ตœ๋Œ€ ํƒ€๊นƒ ์ ์œ ์œจ (e.g., ≤10%) ๊ณ„์‚ฐ
  5. ์•ˆ์ „๊ณ„์ˆ˜(SF) ์ ์šฉ
    • ์ผ๋ฐ˜์ ์œผ๋กœ 10–100๋ฐฐ ์ ์šฉ
    • (e.g. ์˜ˆ์ƒ MABEL: 1 mg → ์‹œ์ž‘ ์šฉ๋Ÿ‰: 0.01–0.1 mg)

๐Ÿ“Š MABEL ๊ณ„์‚ฐ ์‹ค๋ก€ (ํ•ญ์ฒด์•ฝ๋ฌผ)

ํ•ญ๋ชฉ ์ˆ˜์น˜ ์˜ˆ์‹œ

in vitro ECโ‚…โ‚€ 0.05 nM
์˜ˆ์ƒ Cแต‰แถ แถ  (ํ˜ˆ์ค‘) 0.1 nM
์˜ˆ์ƒ ํ˜ˆ์ค‘ ๋†๋„ 0.1 nM ≈ 15 ng/mL
Vd (๋ถ„ํฌ์šฉ์ ) 5 L
์šฉ๋Ÿ‰(Dose) 15 ng/mL × 5 L = 75 µg
์•ˆ์ „๊ณ„์ˆ˜ 10x ์‹œ์ž‘ ์šฉ๋Ÿ‰ = 7.5 µg

๐Ÿ“š ์‹ค๋ฌด ์ฐธ๊ณ ์ž๋ฃŒ

  • EMA Guideline (2017): Strategies to mitigate risk in first-in-human trials
  • Leach et al., Nature Reviews Drug Discovery (2010): MABEL and first-in-human design
  • Shah et al., Clinical Pharmacology & Therapeutics, 2020
  • FDA MABEL Q&A
๋ฐ˜์‘ํ˜•